The a2 Milk Company will hand its shareholders a one-off payment of $300 million, after clearing the final Chinese regulatory hurdle that has hung over its big bet on a factory south of Auckland.
The dual-listed dairy company, which trades on both the New Zealand and Australian exchanges, declared the special dividend of 41.36 New Zealand cents a share late last week. It will be paid on 24 July, with the shares trading without the dividend attached from 8 July and the record date a day later on 9 July. The payout is fully franked, which adds extra value for the company’s Australian shareholders.
The trigger was an approval from China’s market regulator. On 22 June the company told the market that the State Administration for Market Regulation had agreed to let it move two China-label infant formula registrations onto the a2 brand. Those registrations were tied to a2’s purchase of the Pōkeno manufacturing site in the Waikato, and shifting them across was the last piece of a deal that has been more than a year in the making.
Chinese registrations are the gatekeepers of that market. Without one, a brand cannot legally sell tinned infant formula on Chinese shelves, and the regulator hands them out sparingly. Securing the right to put the a2 name on formula canned at Pōkeno means the company can finally run its own New Zealand factory end to end for its most important product, rather than relying on outside processors.
Chair Pip Greenwood said the board was pleased to declare the dividend after clearing the regulatory hurdles, and that the payment “reflects our commitment to delivering shareholder returns while maintaining disciplined capital management”. Chief executive David Bortolussi had earlier described the Chinese approval as a “significant milestone” in the company’s China growth strategy.
Investors liked it. a2 shares rose around 6 percent in late morning trading on the day of the announcement, extending a run that has seen the once-battered stock claw back much of the ground it lost during its post-pandemic slump. You can read RNZ’s report on the dividend here, and the company’s own market notice on the NZX.
The Pōkeno story explains why the milestone matters so much. a2 bought the plant from Yashili, a subsidiary of Chinese dairy giant Mengniu, for $282 million. At the same time it sold out of Mataura Valley Milk, its Southland processing business, offloading the stake to Open Country Dairy in a deal that completed at the end of October last year and returned the company about $100 million. The two moves together amounted to a swap, trading a part-owned plant in the deep south for full control of a site close to its Auckland base and its main export ports.
The company has said it plans to spend a further $100 million over several years lifting capacity and capability at Pōkeno, and to employ more than 100 extra people there over time. When a2 first announced the purchase it called the move a step change, framing it as the moment the brand stopped being a marketing company that bought in its product and became a manufacturer in its own right.
That shift comes as a2 is enjoying a rare patch of strong trading. In the first half of its 2026 financial year the company reported revenue up 18.8 percent to $993.5 million, with its infant formula business growing 13.6 percent and outpacing the wider Chinese market. a2 has climbed to fourth place among formula brands in China, the largest market of its kind in the world, with about 8 percent share. You can read the New Zealand Herald’s coverage of the company lifting its revenue outlook here.
The wider picture is not all tailwinds. China’s birth rate has been falling for years, which over time shrinks the pool of babies that formula makers are chasing. a2 has bucked that trend so far by taking share from rivals and by leaning on the premium end of the market, where Chinese parents have shown a willingness to pay more for brands they trust. The company has also moved to widen its range, announcing earlier this year that it would push into China’s children’s nutrition and supplements market to reduce its reliance on formula alone.
For now, though, the headline is the cash. A $300 million special dividend is a sizeable return for a company that spent the years after the pandemic rebuilding investor confidence, cutting back on the grey-market selling channels that once propped up its sales and steadying a share price that had fallen heavily from its highs. Special dividends are paid on top of a company’s ordinary payouts and usually signal that the board sees more cash on hand than it needs for day-to-day running or near-term investment.
The payment also lands at a useful moment for the New Zealand sharemarket, where dividend-paying blue chips have been in demand from income investors waiting on the Reserve Bank’s next move on interest rates. a2 has not historically been a big dividend payer, having reinvested heavily as it grew, so the move marks something of a coming of age for a company that was once one of the exchange’s fastest-growing names and is now one of its largest.
Shareholders on the register at 9 July will get the payment automatically. The bigger question for the market is whether the Pōkeno deal, now fully unlocked, can turn a2’s recent run of good results into something more durable as it tries to grow in a market where the number of customers is slowly shrinking even as its own slice of it gets bigger.
What do you make of a2 Milk’s $300 million payout and its bet on Pōkeno? Have your say in the comments below.
This article was written by AI, briefed to report the facts, hopefully without some of the bias people bring to the job 🙂
Leave a Reply